Ikena Oncology マネジメント
マネジメント 基準チェック /24
現在、CEO に関する十分な情報がありません。
主要情報
Mark Manfredi
最高経営責任者
US$1.2m
報酬総額
| CEO給与比率 | 45.9% |
| CEO在任期間 | 6.9yrs |
| CEOの所有権 | n/a |
| 経営陣の平均在職期間 | 1.1yrs |
| 取締役会の平均在任期間 | 4yrs |
経営陣の近況
Recent updates
Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)
Jun 01
Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%
Nov 10Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers
Aug 15Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues
May 20Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?
Apr 29We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully
Jan 06Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth
Aug 06Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts
Mar 23Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 21Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?
Feb 19We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate
Nov 02Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans
Jul 13CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$60m |
| Jun 30 2024 | n/a | n/a | -US$67m |
| Mar 31 2024 | n/a | n/a | -US$70m |
| Dec 31 2023 | US$1m | US$569k | -US$68m |
| Sep 30 2023 | n/a | n/a | -US$63m |
| Jun 30 2023 | n/a | n/a | -US$63m |
| Mar 31 2023 | n/a | n/a | -US$66m |
| Dec 31 2022 | US$2m | US$546k | -US$69m |
| Sep 30 2022 | n/a | n/a | -US$52m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$41m |
| Dec 31 2021 | US$5m | US$530k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$63m |
| Jun 30 2021 | n/a | n/a | -US$55m |
| Mar 31 2021 | n/a | n/a | -US$47m |
| Dec 31 2020 | US$606k | US$410k | -US$44m |
報酬と市場: Markの 総報酬 ($USD 1.24M ) は、 US市場 ($USD 647.72K ) の同規模の企業の平均を上回っています。
報酬と収益: Markの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Mark Manfredi (53 yo)
6.9yrs
在職期間
US$1,240,640
報酬
Dr. Mark Manfredi, Ph D., serves as Member of Scientific Advisory Board of Bantam Pharmaceutical, LLC. He has been President, Chief Executive Officer and Director of Ikena Oncology, Inc. since December 201...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 6.9yrs | US$1.24m | データなし | |
| CFO & Head of Corporate Development | 2.6yrs | US$782.32k | 0% $ 0 | |
| Vice President of Investor Relations | less than a year | データなし | データなし | |
| Chief Development Officer | 3yrs | データなし | データなし | |
| Senior Vice President of Finance & Operations | no data | データなし | データなし | |
| Senior Vice President of Clinical Development Operations | 1.1yrs | データなし | データなし | |
| Chief Medical Officer | less than a year | データなし | データなし | |
| Senior Vice President of Technical Operations | less than a year | データなし | データなし |
1.1yrs
平均在職期間
52.5yo
平均年齢
経験豊富な経営陣: IKNAの経営陣は 経験豊富 とはみなされません ( 1.1年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 6.9yrs | US$1.24m | データなし | |
| Independent Director | 8.7yrs | US$130.36k | 0% $ 0 | |
| Chair of Scientific Advisory Board | 4yrs | データなし | データなし | |
| Independent Director | 3.9yrs | US$128.25k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | 4yrs | データなし | データなし | |
| Chairman of the Board | 1.8yrs | US$167.86k | 0% $ 0 | |
| Independent Director | 8.7yrs | US$131.86k | 0% $ 0 | |
| Independent Director | 8yrs | US$126.97k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$117.86k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4yrs | データなし | データなし | |
| Independent Director | 3.6yrs | US$117.86k | 0% $ 0 |
4.0yrs
平均在職期間
62.5yo
平均年齢
経験豊富なボード: IKNAの 取締役会 は 経験豊富 であると考えられます ( 4年の平均在任期間)。